Clinical Study On The Treatment Of Advanced Non-small Cell Lung Cancer With Yifei Prescription Combined With Anlotinb

Objective:To investigate the efficacy and side effects of Yifei Prescription combined withanlotinib in the treatment of advanced non-small cell lung cancer(NSCLC)by means of observing the changes in the short-term improvement,TCM syndrome,KPS score,tumor markers and safety of the two groups.Method:Select a total of 60 patients with stage IV non-small cell lung cancer,according to the standard of diagnosis of TCM and Western medicine,and this experiment's inclusion and exclusion criteria.Divided those patients equally into experimental group(Yifei Prescription combined with anlotinib group)and control group(anlotinib alone group).Size of tumor,TCM syndrome socore,score of life quality,tumor markers and security indicators were recorded before and after thetreatment.SPSS26.0 statistical software was used to analyze the data.Result:1.Comparison of short-term objective efficacy:in the experimental group,ORR was 6.67%and DCR was 80.00%.ORR and DCR in the control group were 3.33%and 76.67%respectively.There was no statistically difference in the objective efficacy between the two groups(P>O.05).2.Efficacy of TCM syndrome:The total effective rate of the trail group was 60.00%,and that of the other group was 23.33%,and the result was with obvious statistical difference(P<0.01).The experimental group had more improvement in fatigue,loss of appetite than the control group,and there were significant statistically differences between the two groups(P<0.01).The experimental group had more improvement in cough,phlegm,dry mouth,night sleep than the control group.And the divergence between the two groups was statistically different(P<0.05).3.Comparison of physical performance:The experimental group's KPS score improved after the trial,and the difference was statistical(P<0.05);KPS score in the control group decreased slightly after the trial,but with no statistically difference compared with before(P>0.05),and the difference of the two groups was seen in data analysis(P<0.05).4.Comparison with the quality of life:There was no significant difference in the functional areas between the two groups after treatment.Compared with the control group,the improvement of the total health status,fatigue,diarrhea,loss of appetite in the experimental group was with obvious statistical difference(P<0.01),and the improvement of insomnia was statistically different(P<0.05).5.Comparison of tumor markers:Experimental group and control group in CEA levels decreased after the treatment,CEA levels of two groups before and after the treatment was with difference,which was statistically(P<0.05),but no obvious stistically difference was found between groups after the treatment(P>0.05),and the level of SCC,NSE,CY21-1 of the two groups before and after treatment were also with no statistical difference(P>0.05).6.Adverse reaction,side effects and safety:Lower incidence of diarrhea was found in the trial group(10.00%vs33.33%),and the difference from the control group was statistically significant(P<0.05),lower chance to feel weak was also seen in the trial group(36.67%vs66.67%),and the discrepancy was obvious in data analysis(P<0.01),and the incidence of the rest of the adverse reactions or side effects was with no statistical difference between groups.Conclusion:Compared with anlotinib,the combination of Yifei Prescription and anlotinib can relieve clinical symptoms and TCM syndromes,improve life quality,and reduce toxic and side effects.